Sanofi has secured FDA approval for venglustat, to be sold as Infilbray, for patients with type 3 Gaucher disease over a certain weight. The once-daily oral drug is the first medicine approved by the agency that targets the neurological symptoms of the rare metabolic disorder, according to the FDA’s announcement Wednesday evening.

That matters because available treatment had addressed systemic manifestations of type 3 Gaucher disease without reaching the brain-related burden of the disease. Type 3 Gaucher disease is driven by deficiency in a certain enzyme, leading to toxic buildup of a specific lipid inside cells and causing enlarged organs, anemia and neurological symptoms including abnormal eye movements and seizures.

The data

According to the FDA, Infilbray was designed to cross the blood-brain barrier and reduce production of the disease-causing lipids, with the goal of lowering their accumulation in cells across the body. That blood-brain-barrier feature is central to the approval, because the barrier has also posed a challenge to developers trying to deliver therapies into the brain.

The approval was supported by the Phase 3 LEAP2MONO study, which enrolled 43 patients. In a February readout cited by BioSpace, Infilbray outperformed enzyme replacement therapy, the current standard of care, on neurological outcomes at 52 weeks and met the trial’s primary endpoint. The drug was also reported to be as good as enzyme replacement therapy at improving non-neurological manifestations such as spleen and liver volumes and hemoglobin levels.

The road here

The FDA had previously granted Infilbray breakthrough therapy, rare pediatric disease and fast-track designations. In a prepared statement, trial investigator Pramod Mistry of the Yale Lysosomal Disease center and Gaucher Disease Treatment Center said clinicians had been able to treat the systemic manifestations of type 3 Gaucher disease while the neurological manifestations remained beyond the reach of available therapies.

The approval also reshapes how Sanofi’s venglustat program is viewed. Sanofi already markets Cerezyme for the systemic but not neurological manifestations of type 3 Gaucher disease, and Cerdelga is approved for a different type of Gaucher disease. Outside Gaucher, venglustat has produced mixed results: in Fabry disease, Phase 3 PERIDOT results in February found no significant benefit on neuropathic and abdominal pain, missing the primary endpoint, though another Phase 3 study remains ongoing in adults on left cardiac ventricular mass index. In other settings, Sanofi discontinued studies in GM2 gangliosidosis, kidney disease and Parkinson’s disease after underwhelming efficacy. This approval therefore stands out as a targeted regulatory win for a molecule whose broader expansion has narrowed substantially.